EU OKs Novartis’ gene therapy Luxturna for rare retinal disease
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Read More
Tag: RPE65
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
